View in EDS HTML Full Text PDF Full Text

Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.

Saved in:
Bibliographic Details
Title: Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.
Authors: Colson AE; Community Resource Initiative, Boston, and Cambridge Health Alliance, Cambridge, Massachusetts (A.E.C.)., Crofoot GE; The Crofoot Research Center, Houston, Texas (G.E.C.)., Ruane PJ; Ruane Clinical Research, Los Angeles, California (P.J.R.)., Ramgopal MN; Midway Immunology & Research Center, Fort Pierce, Florida (M.N.R.)., Dretler AW; Metro Infectious Disease Consultants, Decatur, Georgia (A.W.D.)., Nahass RG; IDCare, Hillsborough, New Jersey (R.G.N.)., Sinclair GI; Prism Health North Texas, Dallas, Texas (G.I.S.)., Berhe M; North Texas Infectious Diseases Consultants, Dallas, Texas (M.B.)., Roberts A; Division of Infectious Diseases, George Washington University School of Medicine and Health Sciences, Washington, DC (A.R.)., Applin S; Community Health Care, Tacoma, Washington (S.A.)., Brinson C; Central Texas Clinical Research, Austin, Texas (C.B.)., Jayaweera D; University of Miami, Miller School of Medicine, Miami, Florida (D.J.)., Workowski KA; Department of Medicine, Division of Infectious Diseases, Emory University, Atlanta, Georgia (K.A.W.)., Shihadeh F; Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.)., Liu SY; Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.)., Klopfer S; Merck & Co., Rahway, New Jersey (S.K., C.L., E.G.R.)., Llamoso C; Merck & Co., Rahway, New Jersey (S.K., C.L., E.G.R.)., Madera S; Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.)., Dvory-Sobol H; Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.)., Rhee MS; Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.)., Rhee EG; Merck & Co., Rahway, New Jersey (S.K., C.L., E.G.R.)., Baeten JM; Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.)., Eron JJ; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.J.E.).
Source: Annals of internal medicine [Ann Intern Med] 2026 Feb; Vol. 179 (2), pp. 168-176. Date of Electronic Publication: 2025 Dec 23.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: American College of Physicians--American Society of Internal Medicine Country of Publication: United States NLM ID: 0372351 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1539-3704 (Electronic) Linking ISSN: 00034819 NLM ISO Abbreviation: Ann Intern Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41429026
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Colson+AE%22">Colson AE</searchLink>; Community Resource Initiative, Boston, and Cambridge Health Alliance, Cambridge, Massachusetts (A.E.C.).<br /><searchLink fieldCode="AU" term="%22Crofoot+GE%22">Crofoot GE</searchLink>; The Crofoot Research Center, Houston, Texas (G.E.C.).<br /><searchLink fieldCode="AU" term="%22Ruane+PJ%22">Ruane PJ</searchLink>; Ruane Clinical Research, Los Angeles, California (P.J.R.).<br /><searchLink fieldCode="AU" term="%22Ramgopal+MN%22">Ramgopal MN</searchLink>; Midway Immunology & Research Center, Fort Pierce, Florida (M.N.R.).<br /><searchLink fieldCode="AU" term="%22Dretler+AW%22">Dretler AW</searchLink>; Metro Infectious Disease Consultants, Decatur, Georgia (A.W.D.).<br /><searchLink fieldCode="AU" term="%22Nahass+RG%22">Nahass RG</searchLink>; IDCare, Hillsborough, New Jersey (R.G.N.).<br /><searchLink fieldCode="AU" term="%22Sinclair+GI%22">Sinclair GI</searchLink>; Prism Health North Texas, Dallas, Texas (G.I.S.).<br /><searchLink fieldCode="AU" term="%22Berhe+M%22">Berhe M</searchLink>; North Texas Infectious Diseases Consultants, Dallas, Texas (M.B.).<br /><searchLink fieldCode="AU" term="%22Roberts+A%22">Roberts A</searchLink>; Division of Infectious Diseases, George Washington University School of Medicine and Health Sciences, Washington, DC (A.R.).<br /><searchLink fieldCode="AU" term="%22Applin+S%22">Applin S</searchLink>; Community Health Care, Tacoma, Washington (S.A.).<br /><searchLink fieldCode="AU" term="%22Brinson+C%22">Brinson C</searchLink>; Central Texas Clinical Research, Austin, Texas (C.B.).<br /><searchLink fieldCode="AU" term="%22Jayaweera+D%22">Jayaweera D</searchLink>; University of Miami, Miller School of Medicine, Miami, Florida (D.J.).<br /><searchLink fieldCode="AU" term="%22Workowski+KA%22">Workowski KA</searchLink>; Department of Medicine, Division of Infectious Diseases, Emory University, Atlanta, Georgia (K.A.W.).<br /><searchLink fieldCode="AU" term="%22Shihadeh+F%22">Shihadeh F</searchLink>; Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.).<br /><searchLink fieldCode="AU" term="%22Liu+SY%22">Liu SY</searchLink>; Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.).<br /><searchLink fieldCode="AU" term="%22Klopfer+S%22">Klopfer S</searchLink>; Merck & Co., Rahway, New Jersey (S.K., C.L., E.G.R.).<br /><searchLink fieldCode="AU" term="%22Llamoso+C%22">Llamoso C</searchLink>; Merck & Co., Rahway, New Jersey (S.K., C.L., E.G.R.).<br /><searchLink fieldCode="AU" term="%22Madera+S%22">Madera S</searchLink>; Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.).<br /><searchLink fieldCode="AU" term="%22Dvory-Sobol+H%22">Dvory-Sobol H</searchLink>; Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.).<br /><searchLink fieldCode="AU" term="%22Rhee+MS%22">Rhee MS</searchLink>; Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.).<br /><searchLink fieldCode="AU" term="%22Rhee+EG%22">Rhee EG</searchLink>; Merck & Co., Rahway, New Jersey (S.K., C.L., E.G.R.).<br /><searchLink fieldCode="AU" term="%22Baeten+JM%22">Baeten JM</searchLink>; Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.).<br /><searchLink fieldCode="AU" term="%22Eron+JJ%22">Eron JJ</searchLink>; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.J.E.).
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220372351%22">Annals of internal medicine</searchLink> [Ann Intern Med] 2026 Feb; Vol. 179 (2), pp. 168-176. <i>Date of Electronic Publication: </i>2025 Dec 23.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+College+of+Physicians--American+Society+of+Internal+Medicine%22">American College of Physicians--American Society of Internal Medicine </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0372351 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1539-3704 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200034819%22">00034819 </searchLink><i>NLM ISO Abbreviation: </i>Ann Intern Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41429026
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.7326/ANNALS-25-01939
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 168
    Titles:
      – TitleFull: Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Colson AE
      – PersonEntity:
          Name:
            NameFull: Crofoot GE
      – PersonEntity:
          Name:
            NameFull: Ruane PJ
      – PersonEntity:
          Name:
            NameFull: Ramgopal MN
      – PersonEntity:
          Name:
            NameFull: Dretler AW
      – PersonEntity:
          Name:
            NameFull: Nahass RG
      – PersonEntity:
          Name:
            NameFull: Sinclair GI
      – PersonEntity:
          Name:
            NameFull: Berhe M
      – PersonEntity:
          Name:
            NameFull: Roberts A
      – PersonEntity:
          Name:
            NameFull: Applin S
      – PersonEntity:
          Name:
            NameFull: Brinson C
      – PersonEntity:
          Name:
            NameFull: Jayaweera D
      – PersonEntity:
          Name:
            NameFull: Workowski KA
      – PersonEntity:
          Name:
            NameFull: Shihadeh F
      – PersonEntity:
          Name:
            NameFull: Liu SY
      – PersonEntity:
          Name:
            NameFull: Klopfer S
      – PersonEntity:
          Name:
            NameFull: Llamoso C
      – PersonEntity:
          Name:
            NameFull: Madera S
      – PersonEntity:
          Name:
            NameFull: Dvory-Sobol H
      – PersonEntity:
          Name:
            NameFull: Rhee MS
      – PersonEntity:
          Name:
            NameFull: Rhee EG
      – PersonEntity:
          Name:
            NameFull: Baeten JM
      – PersonEntity:
          Name:
            NameFull: Eron JJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2026 Feb
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1539-3704
          Numbering:
            – Type: volume
              Value: 179
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Annals of internal medicine
              Type: main
ResultId 1